Range Resources: Piper Sandler Maintains Neutral Rating, PT Down to $39 from $41

Range Resources: Piper Sandler Maintains Neutral Rating, PT Down to $39 from $41

In a recent update, Piper Sandler has maintained its neutral rating on Range Resources Corporation (NYSE: RRC) but has lowered its price target (PT) from $41 to $39. This adjustment comes following the company's second-quarter earnings report and the latest analyst ratings [1].

Piper Sandler's revised PT reflects the company's performance and the broader market sentiment. Despite a 1.8% increase in shares owned by Charles Schwab Investment Management Inc. in the first quarter, the overall institutional ownership stands at 98.93%, indicating a significant interest from major investors [1].

Analysts have mixed opinions on Range Resources, with a consensus rating of "Hold" and an average price target of $43.37. Mizuho, for instance, has increased its price objective to $48.00, while UBS Group and Royal Bank of Canada have set their targets at $42.00 and $45.00, respectively [1].

Range Resources reported earnings per share (EPS) of $0.66 for the quarter, beating analyst estimates of $0.65. The company also announced a quarterly dividend of $0.09, representing a $0.36 annualized dividend and a dividend yield of 1.1% [1].

The company's focus on natural gas exploration and production in the Appalachian region has been a key driver of its performance. However, the recent delay in clinical trials by Vicarious Surgical Inc. (NYSE: RBOT), a company in the surgical robotics sector, has had a ripple effect on the broader market sentiment [2].

Investors should keep a close eye on Range Resources' future earnings reports and any strategic updates from the company. The lowered PT by Piper Sandler serves as a reminder of the potential risks and uncertainties in the energy sector, particularly in the face of fluctuating oil prices and geopolitical tensions.

References:
[1] https://www.marketbeat.com/instant-alerts/filing-range-resources-corporation-nyserrc-shares-purchased-by-charles-schwab-investment-management-inc-2025-08-13/
[2] https://za.investing.com/news/analyst-ratings/piper-sandler-lowers-vicarious-surgical-stock-price-target-on-delayed-clinical-use-93CH-3836983